National letters to Danaher and Cepheid

Colombia’s compulsory license can expand access to HIV drug dolutegravir

MSF welcomes Colombia taking a historic next step towards issuing first-ever compulsory license to increase access to more affordable generic versions of key HIV medicine dolutegravir

Colombia plans to issue compulsory license on HIV drug dolutegravir, expanding access

MSF urges ViiV to withdraw problematic purchasing conditions hindering access to HIV prevention drug CAB-LA

MSF letter to ViiV asking the company to withdraw problematic purchasing conditions for HIV prevention drug CAB-LA

MSF signed onto a letter supporting Colombia’s action to possibly issue a compulsory license to improve access to HIV drug dolutegravir

MSF warned that access to point-of-care CD4 tests for HIV are under threat because Abbott and Becton Dickinson have decided to stop production

Gilead hikes price while liposomal amphotericin B (L-AmB) for treatment of HIV-related cryptococcal meningitis remains unavailable and unaffordable in countries where it’s most needed

With affordable generics likely years away, ViiV must make information public on supply of long-acting cabotegravir and global distribution plan to ensure access for people in high HIV burden low- and middle-income countries

MSF calls on ViiV to urgently dismantle barriers to access for long-acting cabotegravir

At 2022 International AIDS Conference, MSF calls for increased access to long-acting cabotegravir (CAB-LA) for HIV prevention (PrEP).

MSF urges all countries to adopt the guidelines and outlines the actions needed to make the WHO-recommended treatment accessible to people who need it

MSF’s response to ViiV’s announcement for not pursuing a deal for its HIV drug with generics

MSF and co-authors argue in The Lancet HIV that the production of new COVID-19 drugs should not come at the expense of HIV drug supply.